Introduction to the Evolving EGFR-Mutant NSCLC Treatment Landscape

This introductory segment provides an overview of the evolving treatment landscape for EGFR-mutant non-small cell lung cancer (NSCLC) and establishes the key themes for the discussion. Drs. Mark Socinski and Susan Scott review how advances in targeted therapies have transformed frontline management, moving beyond osimertinib monotherapy to combination regimens such as osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA). They discuss how these newer approaches have improved progression-free and overall survival, reshaping expectations for long-term patient outcomes while introducing greater complexity into treatment selection. The conversation highlights the importance of balancing efficacy with treatment burden, individualizing first-line therapy based on patient-specific factors, and considering emerging second-line options, including antibody-drug conjugates and bispecific antibodies. The segment sets the stage for a deeper discussion on optimizing treatment sequencing, managing toxicities, and delivering patient-centered care in EGFR-mutant NSCLC.